The present disclosure relates to a biocompatible, electrically conductive biomaterial capable of carrying the electrical potential of a cardiac impulse. The biomaterial comprises a conductive polymer and a biocompatible component. The conductive polymer comprising an aminomethoxybenzoic acid (AMBA) polymer. The present disclosure also relates to treatments, uses and devices using the biocompatible, electrically conductive biomaterial.

In accordance with some aspects, the present disclosure is directed to medical compositions that comprises (a) a first hydrophilic polymer functionalized with a plurality of first functional groups and (b) a second hydrophilic polymer functionalized with a plurality of second functional groups, wherein the first and second functional groups are selected to react and form covalent bonds upon a change in conditions such that the first and second hydrophilic polymers crosslink with one another. In other aspects the present disclosure is directed to kits that comprise such medical compositions and to medical procedures that utilize such medical compositions.

The present invention relates to stents for the relief of intraocular pressure in patients with glaucoma and in particular to stents with one or more sealed channels, which may be opened following placement of the stent.

The present invention relates to novel biocompatible oxygen gas generating devices that can be implanted into a living subject. In certain embodiments, the oxygen gas generating devices can be used to deliver oxygen gas to tissue in a subject, thereby stimulating tissue growth and repair. In other embodiments, the devices operate by electrolytically splitting endogenous water in a subject. In yet other embodiments, the device further comprises an implantable supercapacitor capable of supplying energy to the oxygen gas generating device.

A proto-device for implantation into soft tissue comprises an oblong device body, biodegradable microfibres adhesively attached to the body, a rigid matrix of biocompatible material enclosing the body and the microfibres. The biocompatible material is dissolvable and/or degradable in aqueous body fluid at a rate substantially superior to the rate of microfibre degradation. The proto-device is one of proto-microelectrode, proto-optical fibre, proto-polymer tube for drug delivery, proto-electrical lead, proto-encapsulated electronics. Also disclosed are uses of the proto-device and methods for its implantation and manufacture.

The purpose of the present invention is to provide an adhesion prevention material capable of exhibiting excellent adhesion preventive effect. This adhesion prevention material concurrently uses: (A) a peptide (A-1) having an amino acid sequence-(X-Pro-Y)n-[wherein X represents an arbitrary defined amino acid, Pro represents proline, Y represents hydroxyproline or proline, and n is an integer between 1 and 10] and/or a peptide (A-2) having an amino acid sequence-(Pro-Y)m-[wherein Pro represents proline, Y represents hydroxyproline or proline, and m is an integer between 1-10]; and (B) a gelatin gel. This adhesion prevention material exhibits a dramatically enhanced adhesion preventive effect as compared with the case where the abovementioned components are used individually, and in particular, has a markedly superior effect against adhesion of tendons.

The present disclosure relates to biodegradable ureteral stents comprising an anti-cancer drug, and to a composition for use in medicine that may be used to ensure patency of a channel, namely a mammal ureter, for example, an obstructed ureter by a urinary stone, neoplasia or by a surgical procedure. The biodegradable ureteral stents (BUS) disclosed in the present disclosure unexpectedly allow a proper release of anti-cancer drugs, thus extending the duration of the treatment and increasing the efficacy of the treatment.

A wound dressing material includes a particle having a crosslinked gelatin derivative, the gelatin derivative having the structure represented by the following formula (1):

GltnNHCHR.sup.1R.sup.2(1)

wherein Gltn represents a gelatin residue, R.sup.1 represents an alkyl group having 1-17 carbon atoms, and R.sup.2 represents a hydrogen atom or an alkyl group having 1-17 carbon atoms, and the particle having a particle size ranging from 1 to 1,000 m.

A shunt prosthesis comprises a synthetic tube having an inner wall defining a fixed inner diameter of the synthetic tube and a layer of hydrogel of a predetermined thickness coating the inner wall of the synthetic tube such that the layer of hydrogel has a fixed outer diameter and such that an inner diameter of the layer of hydrogel defines a diameter of a lumen extending through and defined by the shunt prosthesis. The layer of hydrogel being configured such that the predetermined thickness of the layer of hydrogel is reducable in vivo over a predetmined period of time by controlling the crosslinking density of the layer of hydrogel. A method of controlling flow through a shunt prosthesis is also provided.

A biocompatible material for securing such implantable medical devices, for example by using an adhesive path.